About the Event
COPD is the fourth leading cause of death in the United States, yet there is no therapy on the market to treat these airway blockages. For the one in five COPD patients suffering with these plugs, a treatment would be quite literally a breath of fresh air.
Aer Therapeutics looks to correct this with Aer-01, an inhaled treatment that allows these patients to breathe freely again. An estimated 25M people in the US suffer from COPD, with 5M experiencing airway blockages that can be treated with Aer-01. The market potential in the U.S. alone for this limited scope is $10.5B and grows as you include other mucus related lung diseases.
Join us for a live webinar with Jim Shaffer, CEO of Aer Therapeutics, to find out more about this unique opportunity.